Best Lutetium-177 therapy Doctors Worldwide — TOP 32

Leading expert in Lutetium-177 therapy – Dr. Raphael integrates cutting-edge genomic profiling with targeted radionuclide treatments at Sourasky Medical Center.

• Senior lecturer and PI for multiple clinical trials in oncology
• Specializes in thoracic malignancies and advanced phase clinical trials
• Member of ESMO and IASLC, focusing on innovative treatments
• Leader of the Israeli National Genomic Medicine Initiative in oncology
• Outstanding teacher at Tel-Aviv University Faculty of Medicine

Prof. Merimsky leads the Unit for Orthopedic Oncology at Sourasky Medical Center, specializing in advanced therapies like Lutetium-177.

• Over 41 years of experience of experience in oncology and sarcoma treatment
• ESMO Faculty member for soft tissue and bone sarcoma
• Fellowship-trained at Institut Gustave Roussy in Paris
• Published extensively on bone and soft tissue malignancies

Dr. Kezban Berberoglu is a professor of nuclear medicine at Anadolu Medical Center in Istanbul. She completed training at the Johns Hopkins University School of Medicine in Baltimore. Dr. Berberoglu specializes in nuclear oncology and nuclear cardiology. She treats thyroid and prostate cancers using radioisotope therapies. She is a member of the European Association of Nuclear Medicine.

• Performs Lutetium-177 and Actinium-225 therapies for oncology patients.
• Expert in PET-CT imaging using Gallium 68 for oncology cases.
• Member of the Turkish Nuclear Medicine Association cardiology work group.
• Works at an MTQUA Top 10 world hospital affiliated with Johns Hopkins.

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

2,200 rhinoplasties over 17 years – Dr. Yılmaz works exclusively on noses at Memorial Hospital in Istanbul.

• Trained in facial plastic surgery
• Handles both primary procedures and complex revisions
• Member of the European Academy of Facial Plastic Surgery

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Solak specializes in Lutetium-177 therapy with extensive experience in treating various cancers at Hisar Hospital Intercontinental.

• Completed fellowship at Hacettepe University Cancer Institute
• Worked at The University of Texas MD Anderson Cancer Center
• Expert in breast, testicular, ovarian, lung, and gastrointestinal cancers
• Trained at Istanbul Sisli Etfal Teaching and Research Hospital

Director of oncology hospitalization at Sourasky Medical Center – Dr. Stepfansky specializes in advanced treatment protocols.

• 26 years of experience of experience in oncology, including research roles
• Primary and secondary researcher for phase 1-3 clinical studies
• Specializes in internal medicine and oncology
• Practiced at leading medical centers in Belarus and Israel

Dr. Inna Ospovat leads the nuclear therapy department at Ichilov Clinic, specializing in Lutetium-177 PRRT – a breakthrough for neuroendocrine tumors.

• Specializes in radiation therapy for gastrointestinal and lung cancers
• Trained in oncology and radiation therapy at Hadassah University Hospital
• Member of ASTRO and ISCORT
• Fellowship at PMH University Hospital in Toronto

Specializing in Medical Oncology – Dr. Alemdar focuses on targeted cancer therapies at Medical Park Antalya Hospital Complex.

• 20 years of experience of experience in oncology
• Trained in Internal Medicine and Medical Oncology at Akdeniz University
• Worked at multiple leading hospitals in Turkey

Professor Rifaat Safadi leads the liver disease unit at Hadassah Medical Center, specializing in advanced treatments like Lutetium-177 therapy.

• Over 38 years of experience of experience in gastroenterology and hepatology
• Fellowship-trained at Sinai School of Medicine in New York
• Member of international liver study associations
• Author of numerous articles in hepatology
• Recipient of multiple scientific awards for liver research

Dr. Yaacov Lawrence is the Chair of Radiation Oncology at Sheba Medical Center. He specializes in precision radiation therapy and neuro-oncology. Dr. Lawrence pioneered celiac plexus radiosurgery for pancreatic cancer pain management. He holds the FASTRO designation, one of the highest honors in his specialty.

• Leads the Gastrointestinal Cancer Program at Sheba Medical Center.
• Performs stereotactic radiosurgery for brain tumors and nervous system cancers.
• Authored over 280 scientific publications on personalized radiation protocols.
• Completed radiation oncology fellowship training at Thomas Jefferson University.

Dr. Jair Bar is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He specializes in treating advanced non-small cell lung cancer using personalized immunotherapy and targeted treatments. Dr. Bar holds a PhD in Molecular Biology and leads a research lab focused on immunotherapy resistance.

• Chair of the Israel Lung Cancer Group.
• Board-certified in both Medical Oncology and Radiotherapy Oncology.
• Treats patients at Sheba Medical Center, a top-10 globally ranked hospital.
• Uses molecular and genetic profiling to create precise cancer treatment plans.

Dr. Nir Kleinmann directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is a pioneer in kidney-sparing laser surgery for complex tumors. Forbes and ResultMed named him among Israel’s Best Doctors for 2025 and 2026. Dr. Kleinmann uses a unique dual-laser system to preserve organ function during cancer treatment.

• Completed urological fellowships at Thomas Jefferson University and McMaster University.
• Expert in minimally invasive treatments for UTUC, kidney stones, and prostate cancer.
• Served as a researcher in the OLYMPUS trial for non-surgical chemoablation.
• Fellow of the American Endourology Society with over 60 scientific publications.

Nail Paksoy is a specialist in nuclear therapies for advanced tumors, with a focus on Lutetium-177 therapy at Medipol Bahçelievler Hospital.

• Board-certified in medical oncology with ESMO certification
• Published research on PSMA-based tumor burden in prostate cancer
• Associate professor at Istanbul Medipol University
• Participated in international clinical trials for targeted cancer therapies

Dr. Ahmer Arif Shaikh specializes in oral cancer surgeries with a focus on organ preservation and functional rehabilitation at HCG Manavata Cancer Centre.

• 15 years of experience of experience in Surgical Oncology
• Fellowship-trained in Head & Neck Surgical Oncology
• Expert in major maxillofacial and head & neck surgeries
• Published researcher in the field